EvergoldLongevity’s Simone Rossignol explains why the longevity economy needs a ‘Medicine 3.0’ interface for the 60+ demographic.
The longevity sector in 2026 is a study in paradox. On one side of the “implementation gap,” we see a golden era of bench-top science: epigenetic reprogramming, senolytic cocktails, and the decoding of the Hallmarks of Aging are no longer speculative – they are in human clinical trials. On the other side, however, sits the actual end-user: the 60+ demographic. For this cohort, the multi-billion-dollar promise of cellular immortality often feels like “biological vaporware.”
For the longevity industry to transition from a venture-capital-fueled niche into a scalable economic engine, we must address this disconnect. We don’t just need better science; we need a better interface. We need Medicine 3.0.
The current lie of the land: high science, low utility
The current state of the field is dominated by “Medicine 2.0” – a reactive, disease-centered model that has successfully extended lifespan but failed to protect healthspan. While billions flow into the search for a “longevity pill,” the primary drivers of late-life morbidity – sarcopenia, cognitive decline, and metabolic dysfunction – remain largely unaddressed in the daily lives of the aging population.
The industry is currently obsessed with “longevity hype.” We are fascinated by the idea of reversing aging by 20 years, yet we struggle to ensure a 70-year-old maintains the grip strength necessary to remain independent. This is where the longevity space must pivot. We must move beyond the molecular and into the functional.
The commercial opportunity of sarcopenia: undervalued capital
If I were to identify the most undervalued “Longevity Tech” vertical of 2026, it would not be a new drug; it would be Muscle Preservation. Sarcopenia – the age-related loss of muscle mass and function – is the “silent killer” of the longevity economy. Muscle is not just for aesthetics; it is a metabolic organ and a primary predictor of all-cause mortality. Yet, while the market for GLP-1 agonists has exploded, the market for technologies that facilitate high-intensity resistance training for the elderly is still in its infancy. There is a massive commercial opening for specialized “Osteogenic Loading” tech and digital platforms that treat muscle as a liquid asset to be defended at all costs.
Moving beyond the molecular and into the functional, specifically regarding core integrity and musculoskeletal healthspan, is where the industry must pivot.
Biomarkers as consumer products: the VO₂ max shift
In Medicine 2.0, biomarkers like VO₂ max were confined to elite sports labs or clinical cardiology. In the Medicine 3.0 era, these are becoming everyday consumer products.
The shift from sporadic lab testing to wearable-integrated “Biological Age” scores is the first step in closing the implementation gap. By 2030, the most valuable longevity companies won’t be those selling supplements, but those selling Feedback Loops. When a 65-year-old can see the direct impact of a morning ruck on their real-time VO₂ max or heart rate variability (HRV), the “abstract” concept of longevity becomes a “tangible” daily game.
The compliance problem: the behavioral missing link
The greatest failure of high-science interventions is not efficacy, but compliance. A 99% effective longevity protocol is 0% effective if a patient cannot execute it.
The longevity space needs to stop acting like a laboratory and start acting like a behavioral design studio. Medicine 3.0 is a framework of “Empowerment.” It requires moving away from the “Doctor-as-Authority” model to a “Human-as-CEO” model. We need digital interfaces that integrate longevity protocols into the messy reality of life – accounting for travel, stress, and shifting motivations. Without a behavioral interface, the best science in the world is just shelfware.
Predicting the 2030 pivot: the Centenarian Decathlon
As we look toward 2030, I predict a total category shift toward Premium Longevity Coaching and Concierge Health. This is being driven by the “Centenarian Decathlon” concept – the idea that we must train today for the specific physical tasks we want to perform at 100.
This shift creates a new asset class: Neurological and Physical Capital. High-net-worth individuals are already moving away from traditional wealth management and toward “Healthspan Management.” The 2030 pivot will see the emergence of “Longevity Concierges” who curate bespoke protocols involving Zone 2 training, stability work, and precision pharmacology, all managed through a centralized Medicine 3.0 dashboard.
What needs to change?
The longevity industry must stop selling “forever” and start selling “function.”
To achieve this, we must:
- Incentivize prevention: we need a shift in insurance and healthcare billing that rewards muscle mass maintenance and VO₂ max improvement rather than just treating the fallout of their decline.
- Democratize data: the “Black Box” of clinical biomarkers must be opened. Seniors should own their biological data as clearly as they own their bank statements.
- Humanize the tech: wearables and longevity apps must move past the “Silicon Valley” aesthetic and design for the visual and cognitive needs of the 60+ demographic without being “ageist.”
Closing the Gap
The longevity economy is currently built on a foundation of brilliant science, but its upper floors – the actual delivery of health – are still under construction. By adopting the Medicine 3.0 interface, we can bridge the gap between the lab bench and the breakfast table.
We don’t just need to add years to life; we need to add the infrastructure of life to those years.
The future of longevity isn’t in a lab in 2050 – it’s in the habits of a 65-year-old today.
About Simone Rossignol
Simone Rossignoli is the founder and lead writer of EvergoldLongevity.com, a platform that translates complex biological science into actionable longevity strategies. With nearly three decades of experience as a biology researcher, he has spent his career investigating the fundamental mechanisms of life and health.
A graduate of the University of Rome “La Sapienza,” Simone started this new adventure into the digital space to bridge the gap between high-level research and the public, helping readers navigate the science of aging with clarity and evidence-based insight.
